Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.

Anne-Gaëlle Goubet,Leonardo Lordello,Carolina Alves Costa Silva, Isabelle Peguillet, Marianne Gazzano,Maxime Descartes Mbogning-Fonkou,Cassandra Thelemaque,Cédric Lebacle,Constance Thibault,François Audenet,Géraldine Pignot,Gwenaelle Gravis,Carole Helissey,Luca Campedel,Morgan Roupret,Evanguelos Xylinas,Idir Ouzaid,Agathe Dubuisson,Marine Mazzenga,Caroline Flament,Pierre Ly, Virginie Marty,Nicolas Signolle,Allan Sauvat,Thomas Sbarrato,Mounia Filahi,Caroline Davin,Gabriel Haddad,Jacques Bou Khalil,Camille Bleriot,François-Xavier Danlos,Garett Dunsmore,Kevin Mulder,Aymeric Silvin,Thibault Raoult, Baptiste Archambaud, Shaima Belhechmi,Ivo Gomperts Boneca,Nadège Cayet,Maryse Moya-Nilges,Adeline Mallet,Romain Daillere,Etienne Rouleau,Camelia Radulescu,Yves Allory, Jacques Fieschi,Mathieu Rouanne,Florent Ginhoux,Gwénaël Le Teuff,Lisa Derosa,Aurélien Marabelle,Jeroen Van Dorp,Nick Van Dijk,Michiel S Van Der Heijden,Benjamin Besse,Fabrice Andre,Miriam Merad,Guido Kroemer,Jean-Yves Scoazec,Laurence Zitvogel,Yohann Loriot

Cancer discovery（2022）

引用 14|浏览27

暂无评分

摘要

In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要